Buket Caliskaner Ozturk

Buket Caliskaner Ozturk

Auto-generated profile, based on publicly available information

Buket Caliskaner Ozturk

Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2017 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
VSVolkan Sozer
Volkan Sozer
MKMüge Kutnu
Müge Kutnu
EAErsan Atahan
Ersan Atahan
BOBuket Calıskaner Ozturk
Buket Calıskaner Ozturk
EHErgi Hysi
Ergi Hysi
HUHafize Uzun
Hafize Uzun

25 June 2021 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
BOBuket Caliskaner Ozturk
Buket Caliskaner Ozturk
EAErsan Atahan
Ersan Atahan
AGAysegul Gencer
Aysegul Gencer
DHDeniz Ongel Harbiyeli
Deniz Ongel Harbiyeli
EKEmine Karabul
Emine Karabul
SBSermin Borekci
Sermin Borekci

14 November 2022 in Journal of Asthma
Verified
Journal Article
Closed access
AGAysegul Gencer
Aysegul Gencer
BOBuket Caliskaner Ozturk
Buket Caliskaner Ozturk
SBSermin Borekci
Sermin Borekci
BGBilun Gemicioglu
Bilun Gemicioglu
This study aims to investigate the presence of underlying chronic airway disease in individuals with chronic cough and dyspnea lasting longer than eight weeks and who had previously Coronavirus dis...

21 October 2022 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
CTCuneyt Tetikkurt
Cuneyt Tetikkurt
BOBuket Caliskaner Ozturk
Buket Caliskaner Ozturk
NGNejdiye Gungordu
Nejdiye Gungordu
Pleuroparenchymal fibroelastosis (PPFE) is a rare lung disease with unprecedented features characterized by fibroelastotic changes in the subpleural lung parenchyma affecting the upper lobes. PPFE is usually idiopathic, but it can be caused by infection, autoimmunity, bone marrow or lung transplantation, or a genetic predisposition. Histopathologic examination of lung biopsy samples reveals homogenous subpleural fibrosis and abundant elastic fibers, allowing for a definitive diagnosis. As PPFE mimics many interstitial lung diseases, clinicians face significant difficulties in making a definitive final diagnosis. Since most disease-related comorbid conditions manifest at an advanced stage, invasive tissue sampling for histopathologic evaluation is consistently impossible. Such a patient presentation highlights the importance of an analysis based solely on clinical findings, which would provide a definitive diagnosis without the need for a biopsy. Because of its exceptional and inconceivable presentation, PPFE creates a diagnostic dilemma. In light of our two cases and the literature data, we present a diagnostic assessment score assay that relies solely on clinical manifestations without histopathological tissue verification to shed light on the diagnosis of PPFE. This review focuses on PPFE identification through the use of a diagnostic assessment analysis to improve early disease recognition without the use of invasive diagnostic interventions to obtain biopsy samples for histopathologic evaluation. This analytic approach, while not diagnostic in and of itself, may provide a useful pathway for differential diagnosis and may preclude redundant initiatives.

6 April 2021 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
CTCuneyt Tetikkurt
Cuneyt Tetikkurt
BKBahar Kubat
Bahar Kubat
CKCigdem Kulahci
Cigdem Kulahci
STSeza Tetikkurt
Seza Tetikkurt
BOBuket Caliskaner Ozturk
Buket Caliskaner Ozturk
Idiopathic pleuropulmonary fibroelastosis is an extremely rare lung disease characterized by the combination of fibrosis of the visceral pleura and the fibroelastotic changes transcending in the subpleural lung parenchyma that predominantly affects the upper lobes with accompanying volume loss. It is mostly idiopathic while infection, autoimmunity, bone marrow or lung transplantation and genetic predisposition may be associated with the development of PPFE. The disease is exceptionally rare as approximately ninety cases have been reported in the literature currently. A 35-year-old female presented with exertional dyspnea, dry cough and weight loss. Physical examination demonstrated platythorax, suprasternal notch deepening and fine rales over the upper lobes. Blood count, serum biochemistry, autoimmunity and serologic markers for collagen vascular diseases were within normal limits. Arterial blood gases demonstrated a low pO2 (48 mm Hg) and a high pCO2 (54 mm Hg) values. Chest x-ray showed bilateral parenchymal fibrotic lesions, left pneumothorax, bronchiectasis in the middle and pleural thickening in the upper lung zones while HRCT revealed bilateral apical pleural thickening, traction bronchiectasis, subpleural reticulations, ground-glass opacities and honeycombing in the upper lobes. Bronchoscopy, BAL cytology, smear and culture did not reveal any pathologic findings. Relevant with the clinical, laboratory, radiologic manifestations and the differential diagnosis with other interstitial lung diseases, PPFE was the final diagnosis. The aim of this case report was to present the clinical manifestations of our case. The second crucial objective was to establish a diagnostic scoring system relevant with the literature and the clinical manifestations of the patient.

12 May 2023 in Medicine
Verified
Journal Article
Open access
SBSermin Borekci
Sermin Borekci
IVIlgim Vardaloglu
Ilgim Vardaloglu
NGNejdiye Gungordu
Nejdiye Gungordu
BOBuket Caliskaner Ozturk
Buket Caliskaner Ozturk
HCHazal Cansu Culpan
Hazal Cansu Culpan
BGBilun Gemicioglu
Bilun Gemicioglu
It has been reported that during the coronavirus disease-2019 (COVID-19) pandemic, bronchiectasis patients were adversely affected due to their limited respiratory functions and acute exacerbations which were triggered by viral infections. The increased concern in the population during the pandemic has affected the attitudes of people toward avoiding disease and patients’ treatment compliance. It is unclear whether treatment adherence and anxiety levels of bronchiectasis patients have changed during the pandemic. We aimed to evaluate treatment adherence and anxiety levels in patients with bronchiectasis. A cross-sectional survey was conducted between May and November 2021. A total of 123 patients with bronchiectasis and 110 adults without chronic diseases were included in the control group. Patient demographic information, bronchiectasis follow-up data, and COVID-19 history were recorded. Then, patients filled out “MARS-5 Index” (Medical Adherence Report Scale-5), Beck Anxiety Scale and the Effect of Events Scale (IES-R). Responses of questionnaires were statistically analyzed. Our results showed that the majority of patients with bronchiectasis had high Medical Adherence Report Scale-5 index total scores during the COVID-19 pandemic (86.2%). The total scores on the Beck Anxiety Scale of bronchiectasis patients who did not have COVID-19 were significantly higher than those who had COVID-19 (P = .04). The total scores on the IES-R were found to be significantly higher in the control group (P < .001). No significant difference was found in the total scores on the Beck Anxiety Scale between the patients and the control group. The bronchiectasis patients had high adherence to their current treatment during the COVID-19 period and were less affected by the pandemic and its psychological effects compared to the healthy population. Furthermore, individuals diagnosed with bronchiectasis who were not infected with COVID-19 demonstrated increased levels of anxiety compared to those who were infected with COVID-19 which may be due to their concern about contracting the disease.